Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing igG with FcαRI (CD89) binding

mAbs

Volumn 7, Issue 4, 2015, Pages 743-751

  Jack Borrok, M ^a   Luheshi, Nadia M ^a   Beyaz, Nurten ^a   Davies, Gareth C ^a   Legg, James W ^a   Wu, Herren ^a   Dall’Acqua, William F ^a   Tsui, Ping ^a  

^a MEDIMMUNE   (United States)

Author keywords

ADCC; CD89; FcaRI; IgA; Macrophage; Monoclonal antibody; Neutrophil; Tandem; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; FC(ALPHA) RECEPTOR; IMMUNOGLOBULIN A; LEUKOCYTE ANTIGEN;

ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; RECEPTOR BINDING; SURFACE PLASMON RESONANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG EFFECTS; HEK293 CELL LINE; IMMUNOLOGY; LEUKOCYTE; MALE;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; FEMALE; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LEUKOCYTES; MALE; MICE; MICE, INBRED BALB C; PHAGOCYTOSIS; RECEPTOR, ERBB-2; RECEPTORS, FC; RECEPTORS, IGG;

EID: 84983604625     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1047570     Document Type: Article

References (42)

1. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; http://dx.doi.org/10.1038/nri2744
2. Iannello A, Ahmad A. Role of antibody-dependent cellmediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005; 24:487-99; PMID:16408158; http://dx.doi.org/10.1007/s10555-005-6192-2
3. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating Fc[gamma]Rs, leading to antitumor efficacy. Immunol Cell Biol 2014; 92 (6):475-80; PMID:24732076; http://dx.doi.org/10.1038/icb.2014.26
4. Smyth MJ, Ngiow SF, Teng MWL. Targeting regulatory T cells in tumor immunotherapy. Immunol Cell Biol 2014; 92(6):473-4; PMID:24777313; http://dx.doi.org/10.1038/icb.2014.33
5. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006; 6:1161-73; PMID:17049014; http://dx.doi.org/10.1517/14712598.6.11.1161
6. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuro-blastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999; 17:176-80; PMID:10052355; http://dx.doi.org/10.1038/6179
7. Jung ST, Kelton W, Kang TH, Ng DTW, Andersen JT, Sandlie I, Sarkar CA, Georgiou G. Effective phagocytosis of low her2 tumor cell lines with engineered, aglycosylated igG displaying high Fc gamma RIIa affinity and selectivity. ACS Chem Biol 2013; 8:368-75; PMID:23030766; http://dx.doi.org/10.1021/cb300455f
8. Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs 2010; 2:181-9; PMID:20150767; http://dx.doi.org/10.4161/mabs.2.2.11158
9. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to Fc gamma RIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7:2517-27; PMID:18723496; http://dx.doi.org/10.1158/1535-7163.MCT-08-0201
10. Dechant M, Valerius T. IgA antibodies for cancer therapy. Crit Rev Oncol/Hematol 2001; 39:69-77; PMID:11418303; http://dx.doi.org/10.1016/S1040-8428(01)00105-6
11. Snoeck V, Peters IR, Cox E. The IgA system: a comparison of structure and function in different species. Vet Res 2006; 37:455-67; PMID:16611558; http://dx.doi.org/10.1051/vetres:2006010
12. Fureder W, Agis H, Sperr WR, Lechner K, Valent P. The surface-membrane antigen phenotype of human blood basophils. Allergy 1994; 49:861-5; PMID:7709996; http://dx.doi.org/10.1111/j.1398-9995.1994.tb00788.x
13. Fureder W, Bankl HC, Toth J, Walchshofer S, Sperr W, Agis H, Semper H, Sillaber C, Lechner K, Valent P. Immunophenotypic and functional characterization of human tonsillar mast cells. J Leukoc Biol 1997; 61:592-9; PMID:9129208
14. Monteiro RC, Kubagawa H, Cooper MD. Cellular-distribution, regulation, and biochemical nature of an fcalpha receptor in humans. J Exp Med 1990; 171:597-613; PMID:2137852; http://dx.doi.org/10.1084/jem.171.3.597
15. Albanesi M, Mancardi DA, Jonsson F, Iannascoli B, Fiette L, Di Santo JP, Lowell CA, Bruhns P. Neutrophils mediate antibody-induced antitumor effects in mice. Blood 2013; 122:3160-4; PMID:23980063; http://dx.doi.org/10.1182/blood-2013-04-497446
16. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001; 97:339-45; PMID:11154206; http://dx.doi.org/10.1182/blood.V97.2.339
17. Souto JC, Vila L, Bru A. Polymorphonuclear neutrophils and cancer: Intense and sustained neutrophilia as a treatment against solid tumors. Med Res Rev 2011; 31:311-63; PMID:19967776; http://dx.doi.org/10.1002/med.20185
18. van Egmond M. Neutrophils in antibody-based immunotherapy of cancer. Expert Opin Biol Ther 2008; 8:83-94; PMID:18081538; http://dx.doi.org/10.1517/14712598.8.1.83
19. Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie MJ, Gramatzki M, van de Winkel JGJ, Valerius T. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002; 100:4574-80; PMID:12393717; http://dx.doi.org/10.1182/blood-2002-03-0687
20. Valerius T, Stockmeyer B, vanSpriel AB, Graziano RF, vandenHerikOudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, et al. Fc alpha RI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 1997; 90:4485-92; PMID:9373259
21. van der Steen L, Tuk CW, Bakema JE, Kooij G, Reijerkerk A, Vidarsson G, Bouma G, Kraal G, de Vries HE, Beelen RHJ, et al. Immunoglobulin A: Fc alpha RI interactions induce neutrophil migration through release of leukotriene B4. Gastroenterology 2009; 137:2018-29; PMID:19555692; http://dx.doi.org/10.1053/j.gastro.2009.06.047
22. Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, van der Winkel JG, Leusen JH, et al. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J Biol Chem 2012; 287:25139-50; PMID:22679018; http://dx.doi.org/10.1074/jbc.M112.353060
23. Boross P, Lohse S, Nederend M, Jansen JHM, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 2013; 5:1213-26; PMID:23918228; http://dx.doi.org/10.1002/emmm.201201929
24. Morell A, Skvaril F, Noseda G, Barandun S. Metabolic properties of human IgA subclasses. Clin Exp Immunol 1973; 13:521-8; PMID:4717094
25. Brunke C, Lohse S, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, Royle L, Liew LP, et al. Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody. mAbs 2013; 5:936-45; PMID:24492345; http://dx.doi.org/10.4161/mabs.26396
26. Chintalacharuvu KR, Vuong LUC, Loi LA, Larrick JW, Morrison SL. Hybrid IgA2/IgG1 antibodies with tailor-made effector functions. Clin Immunol 2001; 101:21-31; PMID:11580223; http://dx.doi.org/10.1006/clim.2001.5083
27. Lazar GA, inventor; Xencor Inc., assignee. Fc Polypeptides with Novel Fc Ligand Binding Sites. United States Patent Application No. WO/2005/077981 A2 2005, Aug 25.
28. Kelton W, Mehta N, Charab W, Lee J, Lee C-H, Kojima T, Kang TH, Georgiou G. IgGA: a “cross-isotype” engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions. Chem Biol 2014; 21:1603-9; PMID:25500223; http://dx.doi.org/10.1016/j.chembiol.2014.10.017
29. Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, et al. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia 2009 Jun; 11(6):509-17, 2 p following 517 2010; PMID:19484140; http://dx.doi.org/10.1593/neo.81578
30. van Egmond M, Hanneke van Vuuren AJ, van de Winkel JG. The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis. Immunol Lett 1999; 68:83-7; PMID:10397160; http://dx.doi.org/10.1016/S0165-2478(99)00034-6
31. Mattu TS, Pleass RJ, Willis AC, Kilian M, Wormald MR, Lellouch AC, Rudd PM, Woof JM, Dwek RA. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions. J Biol Chem 1998; 273:2260-72; PMID:9442070; http://dx.doi.org/10.1074/jbc.273.4.2260
32. Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, van de Winkel JGJ, Valerius T. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 2007; 179:2936-43; PMID:17709508; http://dx.doi.org/10.4049/jimmunol.179.5.2936
33. Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 2009; 20:685-91; PMID:19896358; http://dx.doi.org/10.1016/j.copbio.2009.10.011
34. van Egmond M, van Spriel AB, Vermeulen H, Huls G, van Garderen E, van de Winkel JGJ. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of Fc gamma RI (CD64) and Fc alpha RI (CD89). Cancer Res 2001; 61:4055-60; PMID:11358825
35. Hellwig SMM, van Spriel AB, Schellekens JFP, Mooi FR, van de Winkel JGJ. Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infection and Immunity 2001; 69:4846-50; PMID:11447159; http://dx.doi.org/10.1128/IAI.69.8.4846-4850.2001
36. van Egmond M, van Garderen E, van Spriel AB, Damen CA, van Amersfoort ES, van Zandbergen G, van Hattum J, Kuiper J, van de Winkel JGJ. Fc alpha RI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med 2000; 6:680-5; PMID:10835685; http://dx.doi.org/10.1038/76261
37. Balu S, Reljic R, Lewis MJ, Pleass RJ, McIntosh R, van Kooten C, van Egmond M, Challacombe S, Woof JM, Ivanyi J. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol 2011; 186:3113-9; PMID:21257971; http://dx.doi.org/10.4049/jimmunol.1003189
38. Aleyd E, van Hout MWM, Ganzevles SH, Hoeben KA, Everts V, Bakema JE, van Egmond M. Immunoglobulin A enhances NETosis and release of neutrophil extra-cellular traps by polymorphonuclear cells via Fc alpha RI. Eur J Clin Invest 2014; 44:21-2.
39. Rhodes A, Jasani B, Couturier J, McKinley MJ, Morgan JM, Dodson AR, Navabi H, Miller KD, Balaton AJ. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol 2002; 117:81-9; PMID:11789735; http://dx.doi.org/10.1309/4NCM-QJ9W-QM0J-6QJE
40. Luheshi N, Davies G, Poon E, Wiggins K, McCourt M, Legg J. Th1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro. Eur J Immunol 2014; 44:162-72; PMID:24114634; http://dx.doi.org/10.1002/eji.201343351
41. Clark M. IgG effector mechanisms. Chem Immunol 1997; 65:88-100; PMID:9018874; http://dx.doi.org/10.1159/000425634
42. Herr AB, Ballister ER, Bjorkman PJ. Insights into IgAmediated immune responses from the crystal structures of human Fc alpha RI and its complex with IgA1-Fc. Nature 2003; 423:614-20; PMID:12768205; http://dx.doi.org/10.1038/nature01685